Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome, Cladribine, and Sotorasib in R/R AML
NCT07874737Phase 2Not yet recruiting
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells, cladribine and sotorasib in acute myeloid leukemia (AML), sponsored by The Affiliated People’s Hospital of Ningbo University. Primary endpoint: Overall Response Rate at 28 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cellscladribinesotorasib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07874737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874737.